Key words tiapride - carbamazepine - systematic review - alcoholism - withdrawal symptoms
Introduction
Alcohol withdrawal syndrome (AWS) can cause a life-threatening condition that increases
the concerns for the necessity of suitable and rapid treatments. It has been shown
that chronic alcohol consumption induces neuroadaptive changes that involve mainly
the gamma-aminobutyric acid (GABA) receptors central noradrenaline, dopamine, and
glutamate receptors [1 ]
[2 ]. Studies have shown that a reduced neurotransmission in GABAA and an enhanced neurotransmission in glutamatergic pathways results in an imbalance
between inhibitory and excitatory neurotransmitters [3 ], which leads to the nervous system hyperactivity [4 ]. In fact, GABA has an inhibitory effect that suppresses neural activity and thereby
it plays an important role in developing the tolerance and inducing the withdrawal
syndrome in patients with long-term exposure to alcohol [5 ]. Recent studies have also shown that a genetic variation in GABAA receptor subunits affects the risk for developing alcoholism [6 ]. Furthermore, an increased level of dopamine has been reported in patients with
AWS [7 ]. The involvement of other neuromodulators, such as serotonin and corticotropin-releasing
factor, has also been described, which presents the AWS as a complex phenomenon affecting
multiple nerve systems [8 ]. Triggering this complex matrix of receptors and neurotransmitters to reduce the
withdrawal symptoms has been a challenging theme in the recent researches. In this
field, many combinations of medications have been studied. The most common treatment
options are clomethiazole and benzodiazepines. Bonnet et al. [9 ] compared the efficacy of clomethiazole and clonazepam in a prospective observational
study that revealed no significant difference between these 2 medications. A new study
by Sychla et al. [10 ] showed that both diazepam and clomethiazole were equally effective and safe; however,
clomethiazole showed a faster effect, so patients treated with clomethiazole were
treated significantly shorter. Furthermore, benzodiazepines have become worldwide
the first choice of treatment of AWS because clomethiazole-induced respiratory insufficiency
has limited its use in clinical practice [11 ]. A new study in Germany by Verthein et al. [12 ] showed that oxazepam is as effective as clomethiazole in treatment of AWS. Although
benzodiazepines are prescribed vastly in management of AWS [13 ], many side effects such as memory deficits and interactions with other drugs have
been reported frequently [14 ]
[15 ]. The benzodiazepine-induced additive sedation in combination with alcohol can cause
respiratory suppression [16 ]. Furthermore, benzodiazepines can cause additional addiction problems that also
should be taken into consideration [17 ]. Although some beneficial effects of long-term prescription of benzodiazepines in
patients with alcohol dependence have been reported [18 ], they must be prescribed cautiously in clinical practice. Leggio et al. [19 ] reported that the addictive properties of benzodiazepines increase the focus on
non-benzodiazepine GABAergic medications such as carbamazepine (CBZ), which shows
promising effects in clinical studies.
CBZ is an anticonvulsive that is typically used for the treatment of seizure disorders
and neuropathic pain. However, it has been shown to be effective, safe, and well-tolerable
in treatment of AWS [20 ]
[21 ]
[22 ]. Prince and Turpin [23 ] reported the beneficial effect of CBZ in patients with alcohol dependence, but adverse
effects (for example, dizziness, drowsiness, nausea, and vomiting as the most frequent
side effects) and drug interactions may limit its usefulness. CBZ is a potent inducer
of hepatic cytochrome CYP3A4 and is also known to be an inducer of CYP1A2, 2B6, and
2C9/19, so it may reduce plasma concentrations of medications mainly metabolized by
these cytochromes (for example aripiprazole and tacrolimus) through accelerating their
metabolism.
Tiapride (TIA) is a dopamine D2 and D3 receptor antagonist. It is used to treat a
variety of disorders including dyskinesia, negative symptoms of psychosis, and agitation
and aggression in the elderly [24 ]. A combination of CBZ and TIA has been shown to effectively reduce the withdrawal
symptoms without inducing an additive sedation [25 ]. Since dopamine hyperactivity has been linked with AWS, TIA’s antidopaminergic effects
can influence withdrawal symptoms favorably. In this combination therapy, TIA works
as an anxiolytic whereas the hallucinations, delirium tremens and epileptic attacks
by alcohol withdrawal will be targeted by CBZ. In fact, the therapeutic rational is
the combined effect on both seizure risk and psychovegetative symptoms without a significant
risk for an abuse. This combination has also been shown to be safe even in outpatient
settings [26 ]
[27 ]. However, lack of definite proofs and meta-analysis above all leads to uncertainties
in clinical practices. The aim of this study was to review the literature addressing
the efficacy and safety of the combination therapy with CBZ and TIA in treatment of
AWS. We also performed a meta-analysis to examine the results of the relevant studies
in order to render more definite answers if this combination in the clinical practice
is recommendable. To our knowledge, this is the first meta-analysis addressing the
efficacy of this combination therapy in patients with alcohol dependence.
Methods
Study design and data collection
This study is a systematic review that summarizes the findings of previous researches
addressing the efficacy and safety of CBZ and TIA in treatment of alcohol withdrawal
symptoms. We also performed a meta-analysis to compare the outcomes of relevant literature.
We systematically searched electronic databases including PubMed (MEDLINE), EMBASE,
OVID, Cochrane, Google Scholar, and Scopus for human studies with the following keywords:
“triapride” AND/OR “carbamazepin” AND “alcohol withdrawal” OR “alcohol dependence”
OR “alcohol abuse.” The references of the retrieved articles were also scanned to
detect the relevant literature. All potential published studies up to May 2018 have
been reviewed.
Study eligibility criteria
The relevant studies evaluating the effect of the combination therapy with TIA and
CBZ have been considered as eligible. The inclusion criteria were studies on human
subjects, existence of adequate comparative data, and application of standard instruments
for assessment of withdrawal symptoms for proper comparison. Primary search of databases
with mentioned keywords revealed 290 articles, whereby after exclusion the irrelevant
article after initial screening, 7 studies could be selected. The main reasons for
exclusion were irrelevance of basic theme, lack of adequate comparative data, lack
of application a standard method for assessment the AWS, lack of use of a combination
therapy of TIA and CBZ (application of monotherapy), and use of other anticonvulsants
in combination with TIA. Among the selected articles, 2 studies were case reports
(on only 1single case), so these studies have been also excluded because of lack of
the comparative data.
Assessment of alcohol withdrawal symptoms
Most of the involved studies have used the Clinical Institute Withdrawal Assessment
for Alcohol (CIWA) for the evaluation of AWS. CIWA or CIWA-Ar (revised version), is
a 10-item scale that is used to assess the severity of alcohol withdrawal symptoms.
This instrument assesses the 10 common symptoms of alcohol withdrawal (nausea and
vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory
disturbances, visual disturbances, headache and orientation) [28 ]
[29 ]. Each item on the scale is scored independently, and the summation of the scores
correlates to the severity of alcohol withdrawal symptoms. A mild alcohol withdrawal
is defined with a score of≤15, moderate with scores of 16–20, and severe with any
score>20. All items are scored from 0–7, except for the orientation category, which
is scored from 0–4. The maximum score is 67.
Statistical analysis
All the statistical analysis was performed using Comprehensive Meta-Analysis version
2 (Biostat, Englewood, NJ, USA). Statistical homogeneity was checked by χ2 test and I2 using Cochran heterogeneity statistic, in which I2 higher than 75% represents a heterogenic data. By heterogeneity the random effect
model has been used to calculate the weighted mean difference and 95% confidence interval
(CI) [30 ]
[31 ]. Random effects model enables a proper comparison of data between different studies
with little homogeneity with the assumption that the effects being estimated in the
different studies are not identical but follow some similar distributions, which makes
the synthesis of the information possible. Simulations have shown that this model
can provide valid results even under extreme distributional assumptions [32 ]. This model can also be used in assessment of risk factors in meta-analysis setting
[33 ]. By studies in which no control or comparison groups have been assigned, we used
the pre-post model with entering the data of means and standard deviations at the
beginning and end of the study. The Rosenthal conservative estimate of 0.7 was used
as the pre-post correlation [34 ]. We have also performed a sensitivity analysis (leave-one-out analysis) to make
sure that the results were not influenced by a single study. Leave-one-out meta-analysis
involves performing a meta-analysis on each subset of the studies obtained by removing
1 study at a time.
Results
We summarized the major findings of relevant studies assessing the effect or safety
of the treatment with TIA and CBZ in patients going through an alcohol detoxification
program in [Table 1 ]. The combination of TIA/CBZ has been administered in seven studies, in which 6 of
them have reported this combination as a safe and effective treatment option. One
study evaluated the efficacy and safety of the combination of oxcarbazepine (OXC)
and TIA in treatment of AWS, which showed a good efficacy and tolerability in comparison
with clomethiazole. Three of the seven studies that tested the combination treatment
of TIA/CBZ were open clinical studies without assignment of a control group, so we
used the pre-post model in a single group for a proper comparison with other studies.
Two studies were case reports that reported a single case, so they could not be entered
into the meta-analysis because of different study settings. In 4 studies the severity
of the withdrawal symptoms was assessed using the CIWA-Ar scale. This instrument has
been widely used for assessment of AWS [44 ]
[45 ]
[46 ]. In only one study the visual analog scale and the Symptom Checklist-90-Revised
have been used to assess AWS. However, the assignment of a control group (comparison
with clomethiazole and diazepam groups) led to proper assessment of difference between
groups, so the evaluation of mean difference and F change enabled us to enter this
study in our meta-analysis, too. At the end, 5 studies were included in our analysis.
[Table 2 ] shows the design and the major outcomes of the included literature.
Table 1 The major findings of relevant studies assessing the effect or safety of the treatment
with TIA, CBZ, or OXC in patients with alcohol dependency.
Study
Year of publication
Setting/design
Methodology
Major findings
Franz et al. [35 ]
2001
Pilot study
Comparison of combination of TIA and CBZ vs. CLO
The combination of TIA/CBZ was a safe alternative in alcohol detoxification. Vegetative
recovery seemed to be faster with TIA+CBZ.
Lucht et al. [36 ]
2003
Controlled open-label study
Treatment with TIA/CBZ, CLO and DZP in intoxicated vs. non-intoxicated patients
In non-intoxicated patients, the combination of TIA/CBZ was as effective and safe
as the other groups. In intoxicated patients, TIA/CBZ was safe but a lack of efficacy
has been detected in 18% of participants.
Martinotti et al. [37 ]
2010
Randomized, single-blind clinical trial
Comparison of LZP with pregabalin and TIA
All used medications were safe. The efficacy of pregabalin was superior to that of
TIA and LZP.
Soyka et al. [26 ]
2002
Open clinical study
Combination of CBZ/TIA in outpatient alcohol detoxification
CBZ/TIA combination is an effective and safe treatment for outpatient alcohol detoxification
Soyka et al. [27 ]
2006
Open prospective study
Combination of CBZ/TIA in outpatient alcohol detoxification
Additional evidence that a combination of CBZ/TIA is safe and effective by moderate
severity of withdrawal symptoms in an outpatient setting.
Soyka et al. [24 ]
2006
Pooled analysis (retrospective study)
Pooled analysis in 540 patients treated with the combination of CBZ/TIA
Further evidence that a combination of CBZ/TIA is an effective and safe treatment
for alcohol withdrawal treatment.
Croissant et al. [38 ]
2009
Randomized clinical trial
Comparison of the efficacy of the combination of OXC/TIA and CLO
There was no significant difference in safety, efficacy, and tolerability between
the combined treatment of OXC/TIA and CLO. The combination of OXC/TIA is as safe as
CLO in an inpatient setting.
Müller et al. [39 ]
2011
Case series
Combination treatment of Levetiracetam and TIA in 9 alcohol-dependent patients in
an outpatient setting
Combination of levetiracetam and TIA was a safe and effective treatment option for
mild to moderate withdrawal symptoms in outpatient settings.
Gartenmaier et al. [40 ]
2005
Case report
Combination of CBZ/TIA in treatment of alcohol withdrawal symptoms in a patient with
sleep apnea syndrome
This combination treatment was an effective alternative in alcohol withdrawal without
the risk of respiratory depression.
Lepola et al. [41 ]
1984
Controlled clinical trial
Comparison of TIA vs. chlordiazepoxide in acute alcohol withdrawal
Chlordiazepoxide was significantly more effective in reducing the alcohol withdrawal
symptoms in comparison with TIA.
Agricola et al. [42 ]
1982
A double-blind comparison study
The effect of CBZ vs. TIA in treatment of acute alcohol withdrawal syndrome
Both drugs were equally effective in the treatment of alcohol withdrawal symptoms.
CBZ provided faster relief of symptoms
Dieh et al. [43 ]
2007
Case report
Administration of a combined CBZ and TIA in a 45-year-old alcohol-dependent patient
The interaction between CBZ and TIA caused CBZ intoxication with serum levels up to
19 mg/L. This combination seem not to be safe and should be used with cautious.
CBZ: carbamazepine; CLO: clomethiazole; LZP: lorazepam; OXC: oxcarbazepine; TIA: tiapride.
Table 2 Sample size and outcome measures of the studies included in our meta-analysis.
Study
TIA/CBZ group
Comparison group (CLO or BZD)
CIWA-A mean±SD at the beginning of the study
CIWA-A mean±SD at the end of the study
Sample size
CIWA-A mean±SD at the beginning of the study
CIWA-A mean±SD at the end of the study
Sample size
Soyka et al. [26 ] 2002
18.29±4.2
14.64±2.93
50
No comparison group
Soyka et al. [24 ] 2006
12.3±8.3
2.6±2.4
540
No comparison group
Soyka et al. [27 ] 2006
5.0±4.1
2.4±1.2
116
No comparison group
Franz et al. [35 ] 2001
21.0±14.0
1.0±3.2
40
20.0±12.0
1.5±4.0
40
Lucht et al. [36 ] 2003
Mean change: 0.29 F: 1,534
26
Mean change: 0.35 P: 0.224
14
BZD: benzodiazepines; CBZ: carbamazepine; CIWA-A: Clinical Institute Withdrawal Assessment
for Alcohol; CLO: clomethiazole; TIA: tiapride.
[Table 3 ] shows the analysis of heterogeneity with assessment of I2 along with measurement of tau-squared. Since I2 was more than 75% (91.7%), we used the random effect model to enable a proper integration
of study results.
Table 3 The test of heterogeneity among the included studies as calculated by χ2 test and I2 using Cochran heterogeneity statistic.
Model
Test of null (2-tailed)
Heterogeneity
Tau-squared
z-value
p-value
I2
Tau-squared
Standard error
Variance
Tau
Fixed
27.21
<0.0001
91.76
0.115
0.125
0.016
0.340
Random
4.07
<0.0001
-
-
-
-
-
Our meta-analysis, which is shown in [Fig. 1 ], illustrates that the combination of TIA and CBZ could effectively reduce the AWS
assessed by CIWA-A. The efficacy of this combination in treatment of withdrawal symptoms
was significant (p<0.0001, z-value: 4.07). The cumulative analysis shown in [Fig. 2 ] illustrate that the favorable efficacy of this combination therapy has been consistent
over time. Moreover, as a part of sensitivity analysis, we performed a leave-one-out
sensitivity analysis by removing 1 study at a time to confirm that our findings were
not driven by any single study ([Fig. 3 ]).
Fig. 1 Forest plot of the basic analysis using the random effect model. a reference number 24, b reference number 27.
Fig. 2 Forest plot of the cumulative analysis using the random effect model to illustrate
the stability of outcomes through time. a reference number 24, b reference number 27.
Fig. 3 Leave-one-out study analysis as a component of sensitivity analysis showing that
the findings were not driven by any single study.
Discussion
TIA and alcohol dependence
The favorable effect of TIA in promoting abstinence in patients with alcohol dependency
has been reported previously [47 ]. However, further studies in this field reported contradictory results about the
effectiveness of TIA in maintaining alcohol abstinence [48 ]. Since the dopaminergic hyperactivity has been shown to be related to withdrawal
symptoms, the antidopaminergic effect of TIA has been a theme for further investigations
assessing the role of this medication in reducing the severity of withdrawal symptoms.
TIA demonstrates antidyskinetic and anxiolytic activities [49 ]. It has also a low potential for interaction with ethanol and low risk of abuse
[49 ]. In this field, Murphy et al. compared the efficacy of a monotherapy with TIA with
clomethiazole in patients with alcohol dependence and reported that TIA was more successful
in alleviating gastrointestinal and psychological distress but was less effective
in preventing hallucinosis [50 ]. Moreover, studies have shown unsatisfactory results in treating delirium tremens
with a monotherapy with TIA [51 ]. Therefore, its administration in acute alcohol withdrawal should be accompanied
by adjunct therapy for hallucinosis and seizures [49 ]. Not only TIA does not induce the over sedation, but it also does not reduce the
memory function, which has been frequently reported by benzodiazepines [52 ]. TIA selective D2 and D3 dopamine receptor antagonist, whereby its receptor occupancy
does not exceed 80% even at high doses [53 ]. This explains the reasons why TIA causes rarely side effects such as extrapyramidal
symptoms or tardive dyskinesia. This advantage of TIA has been discussed in elderly
patients by whom TIA can be used to treat agitation [54 ] and can improve the clinical symptoms in senile dementia more effectively than risperidone
and with fewer adverse effects [55 ]. The safety of TIA administration is advantageous especially in outpatient setting
[26 ]
[27 ]. Since TIA provides a safe and efficient treatment option, with a good patient compliance
and the little risks for abuse, it can be considered to be administered especially
in outpatient setting by mild to moderate AWS. Furthermore, it is to mention, that
the required dosage in outpatient setting may be lower compared to the dosage given
to inpatient withdrawal. In this regard, Franz et al. [35 ] treated the admitted patients with 300 mg TIA every 4 h up to the maximum daily
dosage of 1200 mg. Soyka et al. [26 ]
[27 ] performed 2 studies in outpatient setting and administered a daily dosage of 300 mg
TIA, which shows a lower required dosage in patients with mild to moderate AWS. Lucht
et al. [36 ] treated the admitted patients with a minimum daily TIA dosage of 600 mg and a maximum
of 1500 mg, which has been gradually reduced to a dosage between 100–300 mg after
10 days. Both Franz et al. [35 ] and Lucht et al. [36 ] described a TIA/CBZ ratio of 1.5 as the optimal efficient dosage for this combination
in inpatient setting. However, the dosage of CBZ used by Soyka et al. was 600 mg in
combination with 300 mg TIA in outpatient individuals (TIA/CBZ ration of 0.5).
CBZ in treatment of addiction to alcohol
CBZ has been the most used medication administered as an adjunct therapy in combination
with TIA. Not only can CBZ be used as prophylaxis for epileptic seizures, but it also
can reinforce the alleviation of psychotic and vegetative symptoms of alcohol withdrawal
when combined with TIA [35 ]. Various mechanisms of CBZ including inhibition of dopamine synthesis and modulation
of glutaminergic, GABAergic, adrenergic, and cholinergic systems have been described
so far [56 ]
[57 ]. Mariani and Levin [58 ] mentioned in their study the necessity of alternatives to benzodiazepines for the
pharmacological treatment of alcohol-related disorders particularly in outpatient
setting. The favorable effect of CBZ in preventing withdrawal seizures and delirium
tremens has been shown previously [59 ]. Seifert et al. [60 ] compared the efficacy of CBZ with clomethiazole in alcohol withdrawal. In this study
CBZ was as effective as clomethiazole in reducing the initial withdrawal symptoms
such as tremor, perspiration, and psychomotor agitation. Moreover, patients treated
with CBZ showed significantly better verbal memory performance in comparison with
clomethiazole [60 ]. Malcom et al. [61 ] compared the effect of lorazepam and CBZ in outpatient alcohol withdrawal and showed
that both drugs were equally effective. However, CBZ is associated with lots of drug
interactions, so other studies have recommended valproate as a better alternative
to CBZ regarding tolerability [62 ]. A literature review performed by Prince and Turpin [23 ] failed to approve the safety of CBZ application in alcohol withdrawal. However,
the interaction between CBZ and alcohol remains still unclear. In this regard, Piekoszewski
et al. [63 ] assessed the effect of ethanol on the pharmacokinetic and pharmacodynamic of CBZ
in epileptic patients with alcohol dependence. Their study showed that ethanol does
not influence the pharmacodynamic of CBZ in acute drug intoxication. Schick et al.
[64 ] reported that both CBZ and OXC were similarly effective in stabilization of vegetative
parameters and improvement in the cognitive processing speed. However, this study
showed the beneficial effect of OXC in comparison with CBZ because of less drug interactions
[64 ]. Nevertheless, studies have shown contradictory results regarding the usefulness
of OXC in alcohol withdrawal. In this regard, Koethe et al. [65 ] found no significant difference in normalization of vegetative parameters, craving,
or improvement of psychopathological parameters between OXC and placebo in treatment
of AWS. Since OXC reduces the glutamatergic transmission at corticostriatal synapses,
it has been supposed that this medication can have favorable effect in maintaining
abstinence in patients with alcohol dependence. Croissant et al. [66 ] showed that the abstinence duration was similar between patients treated with OXC
and those treated with acamprosate. Furthermore, Martinotti et al. [67 ] demonstrated a favorable significant efficacy of high dosage of OXC (1500–1800 mg/day)
in prevention of alcohol-relapse, whereas the lower dosage of OXC showed a weaker
effectiveness that was comparable to naltrexone. Since OXC exerts mood stabilization
effect, some studies have discussed that the favorable influence of OXC in preventing
relapse in alcohol dependence is because of its positive effects on comorbid psychiatric
disorders [67 ]. The mechanism of action of OXC is not yet fully understood. Some studies have also
reported a dopaminergic effect if OXC which has caused rarely even psychotic symptoms
[68 ]. However, OXC has been shown to be still a valuable alternative to benzodiazepines
because of its better safety profile than classical anticonvulsant drugs and the absence
of addictive properties [69 ]
[70 ].
Safety of the combination of TIA and CBZ in treatment of alcohol withdrawal symptoms
Until now, studies have shown a good tolerability of this combination. However, some
case reports have shown unwanted adverse effects of this treatment, so it should still
be prescribed with caution. Diehl et al. [43 ] report a CBZ intoxication in a patient treated with the combination of CBZ and TIA.
This result shows that the metabolism of CBZ could have been blocked or decelerated
by TIA. There are still limited investigations addressing the interactions between
TIA and other drugs. In this regard, Nozaki et al. [71 ] reported a case of neuroleptic malignant syndrome (NMS) induced by a combination
therapy with tetrabenazine and TIA in a patient with Huntington’s disease at the terminal
stage of recurrent breast cancer. Another case of NMS in an alcoholic patient who
received TIA has also been reported, which had led to patient’s demise [72 ]. Furthermore, another study showed an induced Parkinsonism with a combination of
TIA and donepezil since the cholinergic effect of donepezil combined with antidopaminergic
effect of TIA had caused an acetylcholine/dopamine imbalance [73 ]. These reports show that the adverse effects of TIA, although rare, can cause life-threatening
situations, although there are numerous studies that support the safety and effectiveness
of this drug in management of alcohol dependence. In this field, Shaw et al. [74 ] reported that self-esteem and the subjective satisfaction with life can also be
improved by TIA in alcoholic patients. The good tolerability of this medication and
low risk of side effect have been reported frequently [74 ]
[75 ]
[76 ]
[77 ]. All these studies, inclusive our meta-analysis, prove that TIA can play an important
role management of alcoholism. However, its prescription should be initiated after
the patients’ informed consent.
This study
In our study, we reviewed the studies that had assessed the combination of TIA and
CBZ as a possible alternative for benzodiazepines and clomethiazole. Our meta-analysis
shows that this combination can reduce the withdrawal symptoms effectively (p<0.0001).
These results show that TIA and CBZ can effectively complete and intensify each other’s
influence in reducing AWS to treat vegetative symptoms as well as providing a good
protection against epileptic attacks by increasing the seizure threshold. According
to Franz et al. [35 ], the combination of TIA/CBZ could reduce the occurrence of seizures more effectively
compared to clomethiazole. Moreover, the effect of TIA/CBZ has been reported to be
faster than clomethiazole [35 ].
In our meta-analysis, we could not analyze or compare the dosages used in each study
since we have evaluated the efficacy of the general prescribed treatment in comparison
with a control group in that single study. Our analysis showed that the applied treatment
with the mentioned dosage exerts a significant effect in reducing AWS. However, it
seems that the less severe vegetative symptoms in outpatient cases lead to lower required
dosage of TIA, whereby the CBZ dosage seems to be similar between inpatient and outpatient
settings.
Our meta-analysis was only able to approve the efficacy of combination of TIA/CBZ
as an appropriate treatment option, whereas the safety of its administration still
has to be proven by further investigation.
Conclusion
Our study shows that the combination of TIA/CBZ is an effective treatment in management
of AWS in patients with alcohol abstinence. However, the safety of this combination
could not be proved, so we recommend its prescription after an informed consent. In
cases of intolerance, OXC is a valuable alternative to CBZ, which can be taken into
consideration.
